Abstract:Overexpression of the human epidermal growth factor receptor (HER) family has been implicated in ovarian cancer because of its participation in signaling pathway regulating cellular proliferation, differentiation, motility, and survival. Currently, effective diagnostic and therapeutic schemes are lacking for treating ovarian cancer, and consequently ovarian cancer has a high mortality rate. Although HER2 receptor expression does not usually affect the survival rates of ovarian cancer to the same extent as in breast cancer, it can be used as a docking site for directed nanotherapies in cases with de novo or acquired chemotherapy resistance. In this study, we have exploited a novel gold nanoshell-based complex (nanocomplex) for targeting, dual modal imaging, and photothermal therapy of HER2-overexpressing and drug-resistant ovarian cancer OVCAR3 cells in vitro. The nanocomplexes are engineered to simultaneously provide contrast as fluorescence optical imaging probe and a magnetic resonance imaging agent. Immunofluorescence staining and magnetic resonance imaging successfully show that nanocomplex-anti-HER2 conjugates specifically bind to OVCAR3 cells as opposed to the control, MDA-MB-231 cells, which have low HER2 expression. In addition, nanocomplexes targeted to OVCAR3 cells, when irradiated with near-IR laser, result in selective destruction of cancer cells through photothermal ablation. We also show that near-IR light therapy and the nanocomplexes by themselves are noncytotoxic in vitro. To the best of our knowledge, this is the first successful integration of dual modal bioimaging with photothermal cancer therapy for treatment of ovarian cancer. Based on their efficacy in vitro, these nanocomplexes are highly promising for image-guided photothermal therapy of ovarian cancer, as well as other HER2-overexpressing cancers. Mol Cancer Ther; 9(4); 1028-38. (C) 2010 AACR.

The selection and primary characterization of a 12mer peptide targeting ovarian cancer cells

A molecularly targeted theranostic probe for ovarian cancer.

Screening and Identification of a Specific Binding Peptide to Ovarian Cancer Cells from a Phage-Displayed Peptide Library

Selection and identification of a specific peptide binding to ovarian cancer cells from a phage-displayed peptide library

In Vitro Screening of Ovarian Tumor Specific Peptides from a Phage Display Peptide Library

A Novel Peptide Specifically Targeting Ovarian Cancer Identified by in Vivo Phage Display.

In Vivo Screening with Ph . D .7 TM and Identification of Ovarian Cancer A 2780 Cell Targeted

Cell Adhesion and Invasion Inhibitory Effect of an Ovarian Cancer Targeting Peptide Selected Via Phage Display in Vivo

Identification of a Peptide for Folate Receptor Alpha by Phage Display and Its Tumor Targeting Activity in Ovary Cancer Xenograft

The selection and characterization of the peptides binding to the cells and tissues of gastric carcinoma

Peptidome Characterization of Ovarian Cancer Serum and the Identification of Tumor Suppressive Peptide ZYX36-58

Characterization of a DNA Aptamer for Ovarian Cancer Clinical Tissue Recognition and in Vivo Imaging

In Vivo Selection of Phage Sequences and Characterization of Peptide-Specific Binding to Breast Cancer Cells

Affinity Maturation of an Ovarian Cancer‐Targeting Peptide

Targeting primary and metastatic ovarian cancer with a peptide derived from the human NAF-1/CISD2 protein

SCREENING AND IDENTIFICATION OF SERUM BIOMARKERS OF OVARIAN CARCINOMA BY THE TRANSPLANTED TUMOR IN NUDE MOUSE AS THE MODEL

LC-MS/MS Analysis of Ovarian Cancer Metastasis-Related Proteins Using a Nude Mouse Model: 14-3-3 Zeta As a Candidate Biomarker.

Efficient Inhibition of Intraperitoneal Human Ovarian Cancer Growth by Short Hairpin RNA Targeting CD44.

VEGF-targeted short hairpin RNA inhibits intraperitoneal ovarian cancer growth in nude mice.

Design and application of prodrug fluorescent probes for the detection of ovarian cancer cells and release of anticancer drug

The Influences of a Targeting Peptide on the Ovarian Cancer Cell Motility